XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?
XBI's lower fees and 155-stock portfolio contrast sharply with FBT's concentrated 30-holding approach, though FBT has experienced less volatility over the past five years.
XBI's lower fees and 155-stock portfolio contrast sharply with FBT's concentrated 30-holding approach, though FBT has experienced less volatility over the past five years.
BELLINGS Intelligence Score: 10
Why it matters
This is a routine comparative analysis of two biotech ETFs, reflecting ordinary market commentary without implications for credit markets or systemic impact.
Sources
The Motley Fool
XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?
XBI's lower fees and 155-stock portfolio contrast sharply with FBT's concentrated 30-holding approach, though FBT has experienced less volatility over the past five years.
Nasdaq
XBI vs. FBT: Broad Biotech Exposure or Concentrated Bets?
Key PointsState Street SPDR S&P Biotech ETF carries a lower expense ratio of 0.35% compared to First Trust NYSE Arca Biotechnology Index Fund.